Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapted pyrexia management with adjuvant dabrafenib + trametinib in Japan (CDRB436F2301 comparison)
jRCT1080224725Phase 4Completed
- Start
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma. Primary endpoints: Incidence of grade 3/4 pyrexia, Pyrexia-related hospitalization and 1 more. Started Jun 2019; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT1080224725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224725.